Build Redundancy Into the Supply Chain—and Own the Critical Steps
Ophthalmic products depend on specialized inputs: medical-grade optics and polymers, precision lasers and sensors, sterile injectables and surgical packs. A single-source dependency anywhere in that chain is a dormant impediment waiting for a geopolitical shock, a port closure, or a supplier’s bankruptcy to activate it—advisors warn that for device makers without qualified backup suppliers, one unexpected event can become an eighteen-month problem.8 The pandemic made the lesson systemic: shortages were severe enough that the OECD now treats secure medical supply chains as a cornerstone of resilient health systems, and the FDA has stood up a dedicated office to anticipate device supply disruptions.9
The frictionless posture is dual-sourcing for every critical input, near-shoring where lead times matter most, and selective vertical integration in the steps that define the product’s clinical value. The strategic terrain rewards it: commercial estimates vary considerably depending on the products included, but they consistently project continued growth across ophthalmic diagnostics, surgical devices, and vision-care technology.10 Two shifts are especially important. AI-enabled retinal-screening systems can analyze images and provide preliminary results in near real time, potentially reducing delays in specialist review. Procedures are also continuing to move toward ambulatory surgery centers; for most comparable services in 2026, Medicare ASC payment rates are 46 percent lower than hospital outpatient department rates.11 These trends can increase demand for efficient, compact equipment and standardized supplies designed for outpatient care. Owning those capabilities in-house turns market disruption into a moat. The CEO’s role is not to manage logistics but to insist that the operating plan is stress-tested annually against the question: which single failure could stop us, and have we removed it?
Remove the Internal Frictions Leaders Create
The most persistent impediments in most companies are self-inflicted: approval chains that require five signatures for routine decisions, functions that hoard information, incentive systems that reward departments for optimizing locally while the enterprise stalls. The scale of the waste is measurable. Research published through Harvard Business Review estimates that excess bureaucracy drains more than $3 trillion a year from the U.S. economy,12 and a survey of more than 7,000 managers found employees spending an average of 28 percent of their time—more than a day each week—on bureaucratic chores, with two-thirds saying bureaucracy significantly slows decision-making.13 In a clinical business, these frictions carry an added cost: every internal delay eventually becomes a patient waiting longer for sight-saving care.
Operating without impediment internally means pushing decision rights to the people closest to the information, with clear guardrails rather than clearances—a design task that scholars of organizational economics have long identified as a prime determinant of competitiveness.14 It means a small number of enterprise metrics—time from referral to procedure, first-pass claim acceptance, product-development cycle time—that every function shares, so that no team can win while the company loses. And it means the CEO modeling the behavior personally: killing standing meetings that inform no decision, answering escalations within a day, and treating bureaucratic accumulation the way manufacturers treat waste on a production line—as something to be measured and relentlessly removed.
Convert External Stakeholders Into an Early-Warning System
Payers, ophthalmologists, optometrists, hospital systems, ambulatory surgery centers, and patient advocacy groups are usually managed as audiences. Managed well, they are radar. Reimbursement policy shifts, referral pattern changes, and emerging clinical evidence requirements almost never arrive without warning—the warning simply arrives in rooms where the company is not present. In MDaudit’s 2025 customer dataset, the total at-risk amount per organization associated with external payer audits rose 30 percent.15 Yet the cataract prior-authorization episode showed the counter-lesson: organized ophthalmology, present in the right rooms and armed with documentation, reversed most of a national payer policy within a year. A CEO who invests personal time in clinical advisory boards, payer relationships, and societies such as the AAO and ASCRS buys the one asset that neutralizes most impediments: time to prepare.
The same logic applies to capital. Impediments become crises only when a company lacks the balance-sheet room to absorb them. Maintaining conservative leverage and a genuine liquidity cushion is not timidity; it is what allows a leader to treat a supply shock or a payer dispute as a problem to be solved rather than an emergency to be survived.
The CEO’s Real Job: Designing for Flow
None of these disciplines is glamorous, and none can be delegated entirely. Together they amount to a redefinition of the chief executive’s role in a regulated, clinical business. The CEO of an ophthalmology company is not primarily a dealmaker or a visionary; the CEO is the architect of flow—the person accountable for ensuring that ideas move to products, products move to patients, and payments move to the balance sheet without avoidable resistance at any joint.
It is an apt metaphor for the field itself. Ophthalmology exists to restore clarity where vision has failed—to remove the impediments between a person and the world they need to see. The companies that will lead this sector are those whose leaders apply the same principle to the enterprise: find where the organization’s vision blurs, understand why, and engineer the clarity that lets it see the road ahead.
